患者对大麻用于炎症性肠道疾病的看法:一个多中心调查调查
Mohammed El-Dallal1, Kelsey L Anderson2, Ariana Saroufim3
1Division of Gastroenterology, Marshall University School of Medicine, Huntington, WV (Mohammed El-Dallal).
Annals of gastroenterology
|November 29, 2023
概括
许多炎症性肠病患者使用大麻来缓解疼痛和炎症,但人们仍然担心成和伤害. 需要进一步的研究来了解大麻.
科学领域:
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 在炎症性肠道疾病 (IBD) 患者中,大麻使用率的增加.
- 对大麻治疗IBD症状的治疗潜力越来越感兴趣.
- 需要了解患者对大麻在IBD中的有效性和安全性的看法.
研究的目的:
- 为了调查IBD患者关于他们大麻使用模式.
- 评估大麻对IBD症状的自我报告影响.
- 评估患者对大麻在IBD的安全性和疗效的看法.
主要方法:
- 一项多中心的匿名调查,对166名符合条件的IBD患者进行了调查.
- 调查收集了有关人口统计,临床变量和对大麻的态度的数据.
- 统计分析包括千平方测试和ANOVA,以根据大麻使用情况 (罕见/从未,当前,前).
主要成果:
- 目前的大麻使用者占研究人口的26.5%.
- 大多数患者认为大麻可以缓解IBD炎症 (53%) 和疼痛 (80%).
- 超过70%的人认为大麻的风险低至中等,但对成的担忧因使用群体而异.
结论:
- 肠胃炎症患者认为大麻对疼痛和炎症有好处,但对成和伤害存在担忧.
- 目前的成者与非成者之间对成的看法存在重大差异.
- 进一步的研究对于阐明大麻在IBD管理中的真正益处和风险至关重要.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Drugs for Treatment of Ulcerative Colitis in IBD
145
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
145
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143


